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ceding text, only 6 of these
dently classiﬁed as likely p
(i.e., 6 of 3,600, or approxi
carrier frequency). In viewIn a recent paper by Semsarian et al. (1), several
arguments are presented indicating that the preva-
lence of clinically expressed and hypertrophic car-
diomyopathy (HCM) gene carriers has been greatly
underestimated and could be as high as 1:200. This
updated frequency estimate was primarily on the
basis of a genetic analysis, published in 2012, that
demonstrated 22 of 3,600 participants from the Fra-
mingham Heart Study and Jackson Heart Study co-
horts had likely pathogenic or pathogenic sarcomeric
gene variants (2). Although Semsarian et al. (1) stated
that the variants were classiﬁed “using stringent
criteria for pathogenicity,” it is important to note that
since 2012, there have been signiﬁcant advancements
in the tools to aid in variant classiﬁcation (i.e.,
determining whether a variant is benign or
pathogenic).
Technological advances have allowed us to more
comprehensively and efﬁciently interrogate human
genomes, and there are a number of large-scale
efforts, such as the Exome Sequencing Project and
Exome Aggregation Consortium, which have been
publishing genomic data and variant frequencies
from very large populations stratiﬁed by ethnicity.
These large-scale efforts are important for variant
classiﬁcation because they provide population minor
allele frequencies that, when used in concert with
disease prevalence estimates, may push a variant
into a benign or pathogenic category. Furthermore,
databases such as ClinVar (3) and Human Genome
Mutation Database make it easier for us to access
variant classiﬁcations and publications by different
clinical laboratories and groups. Variant data, fromeven just a few short years ago, should be reviewed
through the lens of these new resources, and revisited
accordingly, in this rapidly changing landscape.
As such, we took a closer look at the 22 variants
classiﬁed as pathogenic or likely pathogenic by
Bick et al. (2). The vast majority (20 of 22) of these
variants were missense variants, which tend to be less
straightforward to classify. Interestingly, only 4 of
the 22 individuals actually expressed HCM (but were
not speciﬁed by Bick et al. [2]). Utilizing our criteria
for variant classiﬁcation, which is largely on the basis
of the American College of Medical Genetics and Ge-
nomics and the Association for Molecular Pathology
2015 guidelines for variant interpretation (4) and
utilizes databases and resources listed in the pre-
variants could be conﬁ-
athogenic or pathogenic
mately 1:600 HCM gene
ing ClinVar data, we
observed that the Harvard Laboratory for Molecular
Medicine (whom participated in the original Bick
et al. [2] variant classiﬁcation) currently classiﬁes 12
of the 22 variants as variants of uncertain signiﬁcance
(equating to an HCM gene carrier frequency of 1:360).
Assessment of these 22 variants illustrates the
somewhat subjective and rapidly evolving nature of
genetic variant classiﬁcation. After applying con-
temporary variant classiﬁcation strategies to the 2012
data, the resultant data would not support a frequency
as high as 1:200. Rather, it would seem to continue to
support the 1:500 frequency of the disease more
prevalently referenced in the published data. This
frequency would take into account reduced pene-
trance (i.e., gene-positive, phenotype-negative cases),
as well as HCM caseswith nongenetic causes.With that
said, these numbers will likely continue to change
as our variant interpretation strategies continue
to evolve. More standardized variant classiﬁcation
criteria would be helpful and improvements in that
area have been made (3,4). However, the complexities
of variant classiﬁcation will likely continue to leave
this ﬁeld somewhat in ﬂux, and the example with HCM
presented here is likely just the tip of the iceberg.*Linnea M. Baudhuin, PhD
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Hypertrophic Cardiomyopathy?We thank Dr. Baudhuin and colleagues for their letter
regarding our recent article (1). They raise the very
important and topical issue of DNA variant classiﬁ-
cation in determining whether a genetic ﬁnding is
pathogenic, benign, or a variant of uncertain signiﬁ-
cance (VUS). As Dr. Baudhuin and colleagues would
be aware, major international initiatives are being
established to develop robust and reliable classiﬁca-
tion criteria to determine the pathogenicity of DNA
variants in hypertrophic cardiomyopathy (HCM), and
indeed all other cardiovascular genetic diseases. Such
classiﬁcation systems and variant interpretation need
to take into account rapidly evolving human genetic
databases such as the Exome Aggregation Consortium
(ExAC), 1000 Genomes Project, Exome Variant Server
(ESV), and most recently, the Genomics England
100,000 Genomes Project, as well as in silico tools
(such as polyphen2 and SIFT), functional data, and
cosegregation studies in families.
Signiﬁcantly, the ﬁnal outcome of the genetic
evaluation is “probabilistic,” that is, it is not a “yes/
no” answer but rather a probability that the variant
identiﬁed causes disease on the basis of the available
supporting evidence (2,3). Dr. Baudhuin and col-
leagues correctly point out that over time, variant
classiﬁcations can change due to new information,
and this can change the classiﬁcation from patho-
genic to VUS or benign, and alternatively from VUS to
pathogenic. We agree that this is a product of the
rapid escalation of available genetic information due
to newer, faster, and cheaper sequencing technolo-
gies, and highlights the importance of periodic
re-evaluation of all variants. In HCM, we have previ-
ously reported that reclassiﬁcation is required in up
to 10% of families with HCM (4). Furthermore,
the issues surrounding variant classiﬁcation highlight
the urgent need to have organized collaborative in-
ternational efforts to curate all human disease genesand to develop classiﬁcation systems directly rele-
vant to cardiovascular disease. The recently pub-
lished American College of Medical Genetics and
Genomics guidelines are an important ﬁrst step in this
process, but need signiﬁcant adaptation and modiﬁ-
cation for such guidelines to be reliable and accurate
in the speciﬁc interpretation of variants relevant to
cardiovascular disease. To this end, the recently
developed National Institutes of Health–funded
Clinical Genome Resource (ClinGen) initiative pro-
vides the hope of improving genomic interpretation
by a coordinated international effort from both clin-
ical and research communities, with the key goals to
share data, build knowledge, develop and reﬁne
variant classiﬁcation, and improve care.
Importantly, the revised estimated prevalence
of HCM of up to 1 in 200 people is on the basis of several
factors in addition to the rate of pathogenic mutations
in what are known as highly intolerant sarcomere
genes. Advanced imaging techniques with high-
resolution cardiovascular magnetic resonance provide
more reliable diagnosis by identifying left ventricular
hypertrophy not appreciated with echocardiography,
expanded recognition of the genotype-positive,
phenotype-negative subset, while more comprehen-
sive family-based clinical and genetic surveillance and
higher clinical index of suspicion is resulting in more
asymptomatic patients being identiﬁed with HCM
(Central Illustration in Semsarian et al. [1]). Taking
together all of these considerations, HCM appears
more prevalent than current estimates, promoting
greater visibility for the disease, enhancing diagnosis
and consideration of contemporary treatment options
(5), and ultimately improving care and outcomes in
patients and families with HCM worldwide.Christopher Semsarian, MBBS, PhD, MPH
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